Hepatitis C virus and hepatocellular carcinoma

• Verfasst von: Fiehn, Felix [VerfasserIn]
• Verfasst von: Beisel, Claudia [VerfasserIn]
• Verfasst von: Binder, Marco [VerfasserIn]
• Titel: Hepatitis C virus and hepatocellular carcinoma
• Titelzusatz: carcinogenesis in the era of direct-acting antivirals
• Verf.angabe: Felix Fiehn, Claudia Beisel and Marco Binder
• E-Jahr: 2024
• Jahr: August 2024
• Umfang: 8 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar 25 June 2024, Version des Artikels 25 June 2024 ; Gesehen am 16.12.2024
• Titel Quelle: Enthalten in: Current opinion in virology
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 2011
• Jahr Quelle: 2024
• Band/Heft Quelle: 67(2024) vom: Aug., Artikel-ID 101423, Seite 1-8
• ISSN Quelle: 1879-6265
• DOI: doi:10.1016/j.coviro.2024.101423
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1912918196

Abstract

Chronic hepatitis C virus (HCV) infection is a major cause of hepatic fibrosis and cirrhosis, with a risk for the development of hepatocellular carcinoma (HCC). Although highly effective direct-acting antivirals (DAAs) are available, the incidence, morbidity, and mortality of HCV-associated HCC are still high. This article reviews the current knowledge of the mechanisms of HCV-induced carcinogenesis with a special focus on those processes that continue after virus clearance and outlines implications for patient surveillance after DAA treatment.